JANX vs. VKTX

Last updated Apr 2, 2026

Compare and contrast key facts about Janux Therapeutics, Inc. (JANX) and Viking Therapeutics, Inc. (VKTX).

Performance

JANX vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Janux Therapeutics, Inc. (JANX) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

JANX vs. VKTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
JANX Janux Therapeutics, Inc.	5.14%	-74.22%	398.97%	-18.53%	-33.25%	-21.55%
VKTX Viking Therapeutics, Inc.	-6.31%	-12.57%	116.23%	97.98%	104.35%	-24.34%

Fundamentals

Market Cap JANX : $899.14M VKTX : $3.76B
EPS JANX : -$2.54 VKTX : -$3.19
PB Ratio JANX : 0.94 VKTX : 5.88
Total Revenue (TTM) JANX : $17.88M VKTX : $0.00
Gross Profit (TTM) JANX : $8.44M VKTX : -$208.00K
EBITDA (TTM) JANX : -$144.65M VKTX : -$393.01M

Returns By Period

In the year-to-date period, JANX achieves a 5.14% return, which is significantly higher than VKTX's -6.31% return.

JANX

• 1D: 4.39%
• 1M: 8.12%
• YTD: 5.14%
• 6M: -38.78%
• 1Y: -45.88%
• 3Y*: 6.24%
• 5Y*: —
• 10Y*: —

VKTX

• 1D: 1.29%
• 1M: -1.14%
• YTD: -6.31%
• 6M: 20.42%
• 1Y: 37.85%
• 3Y*: 25.56%
• 5Y*: 39.32%
• 10Y*: 36.57%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

JANX vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JANX

JANX Risk / Return Rank: 18
JANX Sharpe Ratio Rank: 15
JANX Sortino Ratio Rank: 22
JANX Omega Ratio Rank: 20
JANX Calmar Ratio Rank: 16
JANX Martin Ratio Rank: 18

VKTX

VKTX Risk / Return Rank: 59
VKTX Sharpe Ratio Rank: 58
VKTX Sortino Ratio Rank: 58
VKTX Omega Ratio Rank: 62
VKTX Calmar Ratio Rank: 59
VKTX Martin Ratio Rank: 59

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JANX vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	JANX	VKTX	Difference
Sharpe ratio Return per unit of total volatility	-0.58	0.48	-1.06
Sortino ratio Return per unit of downside risk	-0.33	1.14	-1.47
Omega ratio Gain probability vs. loss probability	0.94	1.17	-0.23
Calmar ratio Return relative to maximum drawdown	-0.71	0.81	-1.52
Martin ratio Return relative to average drawdown	-1.19	1.79	-2.98
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

JANX vs. VKTX - Sharpe Ratio Comparison

The current JANX Sharpe Ratio is -0.58, which is lower than the VKTX Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of JANX and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	JANX	VKTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.58	0.48	-1.06
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.39	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.37	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.08	0.12	-0.21

Correlation

The correlation between JANX and VKTX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

JANX vs. VKTX - Dividend Comparison

Neither JANX nor VKTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

JANX vs. VKTX - Drawdown Comparison

The maximum JANX drawdown since its inception was -83.14%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for JANX and VKTX.

Drawdown Indicators

	JANX	VKTX	Difference
Max Drawdown Largest peak-to-trough decline	-83.14%	-90.41%	+7.27%
Max Drawdown (1Y) Largest decline over 1 year	-64.94%	-45.14%	-19.80%
Max Drawdown (5Y) Largest decline over 5 years	—	-78.86%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-89.26%	—
Current Drawdown Current decline from peak	-78.29%	-65.12%	-13.17%
Average Drawdown Average peak-to-trough decline	-51.08%	-59.92%	+8.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.01%	20.36%	+18.65%

Volatility

JANX vs. VKTX - Volatility Comparison

The current volatility for Janux Therapeutics, Inc. (JANX) is 12.78%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 17.70%. This indicates that JANX experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JANX	VKTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.78%	17.70%	-4.92%
Volatility (6M) Calculated over the trailing 6-month period	86.72%	45.64%	+41.08%
Volatility (1Y) Calculated over the trailing 1-year period	79.41%	78.45%	+0.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	133.55%	101.67%	+31.88%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	133.55%	98.98%	+34.57%

Financials